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Abstract D-Dimer is a biomarker of fibrin formation and
degradation. While a D-dimer within normal limits is used
to rule out the diagnosis of deep venous thrombosis and
pulmonary embolism among patients with a low clinical
probability of venous thromboembolism (VTE), the prog-
nostic association of an elevated D-dimer with adverse
outcomes has received far less emphasis. An elevated D-
dimer is independently associated with an increased risk
for incident VTE, recurrent VTE, and mortality. An ele-
vated D-dimer is an independent correlate of increased
mortality and subsequent VTE across a broad variety of
disease states. Therefore, medically ill subjects in whom
the D-dimer is elevated constitute a high risk subgroup in
which the prospective evaluation of the efficacy and safety
of antithrombotic therapy is warranted.
Keywords D-Dimer  Deep vein thrombosis  Mortality 
Prognosis  Pulmonary embolism
Abbreviations
VTE Venous thromboembolism
PE Pulmonary embolism
DVT Deep vein thrombosis
Introduction
D-Dimer is a biomarker of fibrin formation and degradation
[1–3]. It may be elevated not only in patients with acute
thrombosis, but also among the elderly as well as in a
variety of illnesses [4, 5]. While a D-dimer within normal
limits is used to rule out the diagnosis of deep venous
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thrombosis and pulmonary embolism among patients with
a low clinical probability of venous thromboembolism [6,
7], the prognostic association of an elevated D-dimer with
adverse outcomes has received far less emphasis.
Methods
A search of the Pubmed and Cochrane databases was
independently performed by four individuals. The keyword
used for the search was D-dimer in combination with other
words such as prognosis, mortality, recurrence, incidence,
and occurrence. The search was not limited by country or
language and it included prospective and retrospective
observational studies, clinical trials and systematic
reviews. Study selection was initially based on the review
of the title and it yielded a total of 87 articles. The articles
were categorized as follows (some articles fit more than
one category): D-dimer and mortality, D-dimer and occur-
rence of VTE, and D-dimer and recurrence of VTE. The
four individuals reviewed the articles for quality assess-
ment and extracted information about the study population,
study design, statistical analysis, outcomes (symptomatic
DVT, asymptomatic DVT, PE, VTE and mortality), results
and limitations. Based on their methodology, adequacy of
their sample size, and statistical analysis, a total of 37
articles were considered of at least average quality and
were included in this manuscript.
D-Dimer and subsequent occurrence of VTE
Among acutely and critically ill patients, an elevated D-
dimer is associated with an increased risk of a subsequent
occurrence of a first episode of VTE independent of age,
sex, race, body mass index, and medical illnesses [8–12].
In fact, among 7581 acutely ill medical patients enrolled in
the MAGELLAN study, the incidence of a subsequent
VTE was 3.5 times higher in patients with baseline con-
centrations of D-dimer equal or greater than two times the
upper limit of normal compared to those with normal D-
dimer (OR 2.29; 95 % CI 1.75–2.98) [12]. In the general
population, an elevated D-dimer is associated with an
increased risk of a subsequent first episode of VTE among
923 subjects during 8 years of follow-up [13].
In various disease states, D-dimer is associated with the
subsequent first occurrence of VTE and adverse clinical
outcomes. During ischemic stroke, there is activation of the
coagulation and fibrinolytic systems which may be reflec-
ted by elevations in D-dimer [14, 15]. In a prospective
multi-center study including 1,380 stroke patients followed
for 12 months, an elevated D-dimer measured at the time of
hospitalization was independently associated with the
subsequent first occurrence of VTE (OR 3.45; 95 % CI
2.01–8.52) [15].
As a specific pathologic state, cancer is associated with a
higher risk of subsequent first occurrence of VTE, a risk
further amplified by hospitalization, surgical intervention,
or chemotherapy [16]. D-Dimer is significantly higher
among cancer patients who subsequently develop a first
episode of VTE compared to those who do not [17, 18].
Among 821 cancer patients with a twofold increase in D-
dimer concentration, there was a 1.3 fold increase in the
first occurrence of VTE both in univariate (95 % CI
1.1–1.5; p \ 0.001) and multivariate analyses (HR 1.3;
95 % CI 1.2–1.6; p \ 0.001) following adjustment for age,
sex, radiotherapy, chemotherapy, and surgery [17]. The
association of an elevated D-dimer with the first occurrence
of VTE has been validated in multiple studies among
patients with a variety of oncologic pathologies including
colorectal, lung, and gynecological cancer [19–23].
D-Dimer and recurrence of VTE
While the previous studies evaluated the association of D-
dimer with the first occurrence of VTE, recurrent VTE
following an initial episode is associated with an elevated
D-dimer measured 3 months following discontinuation of
anticoagulation therapy [24, 25]. The association of D-
dimer and VTE recurrence is significant among both non-
carriers (HR 2.43; 95 % CI 1.18–4.61) and carriers of
thrombophilia (HR 8.34; 95 % CI 2.72–17.43) [26]. In a
systematic review of seven studies involving 1888 patients
with a first unprovoked episode of VTE, those with an
elevated D-dimer measured following withdrawal of anti-
coagulation therapy had an annual rate of VTE recurrence
of 8.9 % compared to 3.5 % among patients with a normal
D-dimer [27]. In a separate patient level meta-analysis of
the same population, the annual rates of VTE recurrence
were 8.8 and 3.7 % for patients with elevated and normal
D-dimer, respectively [28].
D-Dimer and mortality
An elevated D-dimer is associated with short and long term
increased mortality [12, 29]. In a meta-analysis of five
studies (n = 2,885) of patients with pulmonary embolism,
an elevated D-dimer was associated with increased all cause
30 day mortality (OR 2.76; 95 % CI 1.83–4.14). Further-
more, in a 4 study meta-analysis (n = 1,254) an elevated
D-dimer was associated with a higher 3-month mortality
(OR 4.29; 95 % CI 1.70–10.79) [29].
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The prognostic significance of D-dimer among stroke
patients is mixed. Although one study did not find an
association between D-dimer and mortality [30], others
reported that D-dimer is elevated among stroke patients
who suffer a subsequent vascular death (p = 0.0201) [31].
Furthermore, an elevated D-dimer within the first weeks of
ischemic stroke is associated with poorer survival inde-
pendent of age, stroke type, or severity (HR 6.43; 95 % CI
2.83–14.62; p \ 0.0001) [32].
Among cancer patients, D-dimer may be elevated not
only in the presence of documented VTE but also in the
absence of any detectable thrombus [33]. Elevated D-dimer
is associated with an increased risk of mortality in a variety
of cancers independent of age, sex, documented VTE, and
types of malignancy [17, 33, 34]. In a meta-analysis of 13
studies of lung cancer patients in particular, elevation of D-
dimer was associated with increased mortality (HR 2.06;
95 % CI 1.64–2.58; p = 0.0001) [35].
Like cancer, D-dimer is associated with higher mortality
among patients with cardiovascular disease. In a study of
174 patients with heart failure, a D-dimer [1,435 ng/mL
was associated with increased cardiovascular mortality
(HR 3.25; 95 % CI 1.647–6.414; p = 0.001) [36]. More-
over, in the AtheroGene Study of 1,057 patients with
coronary artery disease prospectively followed for a med-
ian of 6.6 years, an elevated D-dimer was independently
associated with high cardiovascular mortality [37]. Among
patients with aortic dissection, an elevated D-dimer is
associated with increased hospital mortality [38, 39].
In the setting of community acquired pneumonia and
sepsis, elevation in D-dimer is independently associated
with increased mortality [40–42]. Finally, even in the
absence of clinically overt disease, among 17,359 subjects
free of cardiovascular disease and cancer from the
MOLI-SANI prospective cohort study, an elevated D-dimer
was associated with increased mortality over the sub-
sequent 4 years [43].
Limitations
Although multiple studies have demonstrated an associa-
tion between elevated D-dimer and prognosis, no single cut-
point has been identified which consistently optimizes the
prognostic value of the biomarker. The cut-point evaluated
in multiple studies is that which exceeds the conventional
D-dimer cut-off value (500 ng/mL). However, the threshold
for D-dimer exceeded 5,500 ng/mL in one study [44].
D-Dimer concentrations were measured only once in the
majority of the studies.
Comparing clinical outcomes between studies which
utilized different D-dimer assays and cut-points is chal-
lenging. D-dimer assays are not standardized, and some
assays express D-dimer in fibrin equivalent units (FEU),
while others express it in D-dimer units (one D-dimer unit is
approximately two FEU) [33]. Moreover, D-dimer is also
influenced by age [45] and concomitant medical condi-
tions, such as atrial fibrillation, heart failure, peripheral
artery disease and renal failure [36, 46–49]. The elevation
in D-dimer in these patient groups is a limitation for both
the diagnostic and prognostic role of D-dimer, particularly
among the elderly and patients with renal failure among
whom prolonged VTE prophylaxis can be problematic due
to excess inadvertent bleeding [50, 51].
Finally, the outcomes of the studies regarding the
occurrence of VTE events were not consistent across dif-
ferent studies as some included asymptomatic DVT while
others did not. In addition, not all studies ruled out the
presence of asymptomatic thrombus at the time of D-dimer
measurement, and the possibility that the subsequent VTE
episode was due to an existing clot cannot be excluded.
Conclusion
D-Dimer elevation is associated with the risk of first VTE
occurrence, VTE recurrence, and mortality. An elevated D-
dimer is an independent correlate of increased mortality
and subsequent VTE across a broad variety of disease
states. Therefore, medically ill subjects in whom the D-
dimer is elevated constitute a high risk subgroup in which
the prospective evaluation of the efficacy and safety of
antithrombotic therapy is warranted.
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